Suggested remit: To appraise the clinical and cost effectiveness of remdesivir within its marketing authorisation for treating coronavirus disease 2019 (COVID-19) in people with pneumonia requiring supplemental oxygen.
- Status:
- Awaiting development
- Decision:
- None selected
- Process:
- TA
Project Team
- Project lead
- Michelle Adhemar
Email enquiries
If you have any queries please email [email protected]
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 06 October 2020 (10:00) | Scoping workshop |
| 18 August 2020 - 16 September 2020 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
For further information on our processes and methods, please see our CHTE processes and methods manual